

We updated the design of this site on September 25th. [Learn more.](#)

We will be updating this site in phases. This allows us to move faster and to deliver better services.

[Show less](#)

 U.S. National Library of Medicine

**ClinicalTrials.gov**

[Find Studies](#) ▼  
[About Studies](#) ▼  
[Submit Studies](#) ▼  
[Resources](#) ▼  
[About Site](#) ▼

---

Trial record **1 of 1** for: PV-10-MM-31

[Previous Study](#) | [Return to List](#) | [Next Study](#)

## **PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma**

**This study is currently recruiting participants.**

See [▶ \*\*Contacts and Locations\*\*](#)

*Verified September 2017 by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )*

**Sponsor:**


Provectus Biopharmaceuticals, Inc.

**ClinicalTrials.gov Identifier:**

NCT02288897

First Posted: November 11, 2014

Last Update Posted: September 26, 2017

 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. [Know the risks and potential benefits](#) of clinical studies and talk to your health care provider before participating. Read our [disclaimer](#) for details.

**Information provided by (Responsible Party):**

Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. )

[Full Text View](#)

[Tabular View](#)

[No Study Results Posted](#)

[Disclaimer](#)

[How to Read a Study Record](#)

---

## ▶ Purpose

This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine (DTIC), temozolomide (TMZ) or intralesional talimogene laherparepvec as determined by Investigator preference and standard of care in the Investigator's country or region. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms.

<u>Condition</u>	<u>Intervention</u>	<u>Phase</u>
Cutaneous Melanoma	Drug: PV-10 (10% rose bengal disodium) Drug: Dacarbazine, temozolomide or talimogene laherparepvec	Phase 3

Study Type: Interventional

Study Design: Allocation: Randomized

Intervention Model: Parallel Assignment

Masking: Single (Outcomes Assessor)

Masking Description:

Blinded review by independent review committee (IRC) for primary and key secondary endpoints.

Primary Purpose: Treatment

Official Title: PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

### Resource links provided by NLM:

[MedlinePlus](#) related topics: [Melanoma](#)

[Drug Information](#) available for: [Rose bengal](#) [Temozolomide](#)

[Genetic and Rare Diseases Information Center](#) resources: [Melanoma](#), [Familial](#) [Carcinoid Tumor](#)  
[Neuroepithelioma](#)

[U.S. FDA Resources](#)

Further study details as provided by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. ):

Primary Outcome Measures:

- Progression-free survival (PFS) [ Time Frame: Assessed every 12 weeks up to 18 months ]

Secondary Outcome Measures:

- Complete response rate (CRR) [ Time Frame: Assessed every 12 weeks up to 18 months ]
- Duration of complete response [ Time Frame: Assessed every 12 weeks up to 18 months ]
- Overall survival (OS) [ Time Frame: Assessed every 12 weeks up to 18 months ]
- Number of participants with adverse events [ Time Frame: Assessed every 4 weeks until 28 days after last treatment ]

Safety and tolerability will be assessed by monitoring the frequency, duration, severity and attribution of adverse events and evaluating changes in laboratory values and vital signs.

Other Outcome Measures:

- Change in domain scores from baseline using the patient reported Skindex-16 instrument [ Time Frame: Assessed 12 weeks after Day 1 ]

Estimated Enrollment: 225  
Study Start Date: April 2015  
Estimated Study Completion Date: October 2018  
Estimated Primary Completion Date: September 2018 (Final data collection date for primary outcome measure)

<u>Arms</u>	<u>Assigned Interventions</u>
Experimental: PV-10 Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.	Drug: PV-10 (10% rose bengal disodium)
Active Comparator: Chemotherapy or Oncolytic Viral Therapy Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval	Drug: Dacarbazine, temozolomide or talimogene laherparepvec

followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.

#### Detailed Description:

Subjects will be randomized using a 2:1 treatment allocation (i.e. two-thirds of the subjects will receive PV-10).

Subjects in the comparator arm who have completed at least 1 cycle of study treatment and who meet the study protocol definition of disease progression but do not have evidence of visceral metastases will be eligible to enter the crossover portion of the study and receive PV-10. Subjects crossing over must meet all study inclusion and exclusion criteria for clinical laboratories, thyroid function, concurrent or intercurrent illness and pregnancy at the time of crossover.

Assessment of progression will be performed by an Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 criteria. Events signaling progression include increase in size and/or number of lesions, distant or nodal disease progression, or death. All secondary endpoints involving disease response and progression will be based on the IRC determination.

An interim assessment of efficacy and safety will be performed by the IRC when 50% of the events required for the primary endpoint have occurred.

#### ► Eligibility

##### Information from the National Library of Medicine



*Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies](#).*

Ages Eligible for Study: 18 Years and older (Adult, Senior)

Sexes Eligible for Study: All

Accepts Healthy Volunteers: No

#### Criteria

##### Inclusion Criteria:

1. Age 18 years or older, male or female
2. Histologically or cytologically confirmed melanoma

3. Recurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., AJCC Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases)
4. At least 1 measurable Target Lesion that can be accurately measured by calipers or computed tomography (CT) consisting of:
  - at least one cutaneous lesion (each lesion  $\geq 10$  mm in longest diameter or up to 5 lesions having a sum of longest diameters  $\geq 10$  mm); and/or
  - at least one subcutaneous lesion (each lesion  $\geq 10$  mm in longest diameter by CT);
  - where Target Lesions should be at least 10 mm from any other lesion
5. No lesion  $> 50$  mm in longest diameter; and no more than 50 lesions
6. Calculated required PV-10 dose  $\leq 15$  mL (based on total tumor burden)
7. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-2
8. Not a candidate for treatment with an immune checkpoint inhibitor (e.g., failed or did not tolerate prior therapy, or due to co-morbidities, pre-existing autoimmune disease, drug unavailability or standard of care)
9. Not a candidate for targeted therapy with BRAF or combined BRAF/MEK inhibitors (e.g., failed or did not tolerate prior therapy, BRAF V600 wild-type or due to drug unavailability or standard of care)
10. Clinical Laboratories:
  - Absolute neutrophil count (ANC)  $\geq 1.5 \times 10^9/L$  and platelet count  $\geq 100 \times 10^9/L$
  - Creatinine  $\leq 3$  times the upper limit of normal (ULN)
  - Estimated creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR)  $\geq 30$  mL/min/1.73 m<sup>2</sup>
  - Total bilirubin  $\leq 3$  times the upper limit of normal (ULN)
  - Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP)  $\leq 5$  times the upper limit of normal (ULN)
  - Lactate dehydrogenase (LDH)  $\leq 2$  times the upper limit of normal (ULN).
11. Thyroid function abnormality  $\leq$  Grade 2
12. Candidate for at least one comparator drug:
  - Subjects must be candidates for at least one of the designated comparator drugs

Exclusion Criteria:

1. Presence or history of visceral melanoma metastasis
2. Presence of active nodal metastases (e.g., radiologic or clinical evidence of current nodal disease)
3. Presence of more than 50 melanoma lesions

4. Radiation therapy to any Study Lesion within 6 weeks of initial study treatment.
5. Chemotherapy or other systemic cancer therapy within 4 weeks of initial study treatment (6 weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within 12 weeks of initial study treatment
6. Immunotherapy for cancer within 4 weeks of initial study treatment
7. Local treatment (e.g., surgery, cryotherapy, laser ablation) to any Study Lesion within 4 weeks of initial study treatment
8. Anti-tumor vaccine therapy within 6 weeks of initial study treatment.
9. Investigational agents within 4 weeks of initial study treatment.
10. Concurrent or Intercurrent Illness:
  - Impaired wound healing or other extremity complications due to diabetes mellitus in subjects whose Study Lesions are located in an extremity
  - Severe peripheral vascular disease in subjects whose Study Lesions are located in an extremity
  - Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
  - Uncontrolled thyroid disease or cystic fibrosis
  - Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders
11. Pregnancy:
  - Female subjects who are pregnant or lactating
  - Female subjects who have positive serum pregnancy test taken within 14 days of study treatment
  - Female subjects of child-bearing potential who are unwilling to use highly effective contraception (e.g., combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives, intrauterine devices, bilateral tubal ligation, vasectomized partner, sexual abstinence or equivalent measures) for the duration of study treatment
12. Contraindication for all comparators:
  - Subjects with contraindications to all of the designated comparator drugs

## **Contacts and Locations**

--

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number):  
**NCT02288897**

## Contacts

Contact: Eric Wachter, Ph.D. +1 865 769 4011 ext 23 [wachter@pvct.com](mailto:wachter@pvct.com)

## Locations

### United States, California

Sharp Memorial Hospital - Clinical Oncology Research

San Diego, California, United States, 92123

Contact: Cathy Wood 858-939-5062 [cathy.wood@sharp.com](mailto:cathy.wood@sharp.com)

Principal Investigator: Kristen Rice, M.D.

Recruiting

### United States, Florida

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States, 33140

Contact: Christy M Estevez 305-674-2121 ext 53760

[Christina.Estevez@msmc.com](mailto:Christina.Estevez@msmc.com)

Principal Investigator: Jose Lutzky, MD

Recruiting

### United States, Kentucky

University of Louisville School of Medicine

Louisville, Kentucky, United States, 40202

Contact: Mary Healey 502-629-3327 [mary.healey@louisville.edu](mailto:mary.healey@louisville.edu)

Principal Investigator: Charles Scoggins, M.D.

Recruiting

### United States, Missouri

Washington University School of Medicine - Dermatology

Saint Louis, Missouri, United States, 63110

Contact: Mary Tabacchi, CCRC 314-362-8171 [mtabacchi@wustl.edu](mailto:mtabacchi@wustl.edu)

Principal Investigator: Lynn Cornelius, MD

Recruiting

### United States, New Hampshire

Dartmouth-Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 03756  
Contact: Darcie Findley, CCRC 603-650-4595 [darcie.i.findley@hitchcock.org](mailto:darcie.i.findley@hitchcock.org)  
Principal Investigator: Keisuke Shirai, MD

**United States, New Jersey**

Atlantic Health System **Recruiting**  
Morristown, New Jersey, United States, 07960  
Contact: Molly Maurer 973-714-6341 [molly.maurer@atlantichhealth.org](mailto:molly.maurer@atlantichhealth.org)  
Principal Investigator: Eric Whitman, M.D.

**United States, North Carolina**

Wake Forest Baptist Health **Recruiting**  
Winston-Salem, North Carolina, United States, 27157  
Contact: Angela Howell 336-713-3155 [anhowell@wakehealth.edu](mailto:anhowell@wakehealth.edu)  
Principal Investigator: Paul Savage, MD, FACP

**United States, Oklahoma**

Oklahoma Cancer Specialists and Research Institute **Recruiting**  
Tulsa, Oklahoma, United States, 74146  
Contact: Jan Byerly, RN, BSN, OCN 918-505-3201 ext 4076  
[Jan.Byerly@OCSRI.ORG](mailto:Jan.Byerly@OCSRI.ORG)  
Principal Investigator: Edward Yob, DO

**United States, Pennsylvania**

St Luke's University Hospital and Health Network **Recruiting**  
Easton, Pennsylvania, United States, 18045  
Contact: Robyn Rex 484-503-4152 [Robyn.Rex@sluhn.org](mailto:Robyn.Rex@sluhn.org)  
Principal Investigator: Sanjiv Agarwala, M.D.

Penn State Hershey Cancer Institute **Recruiting**  
Hershey, Pennsylvania, United States, 17033  
Contact: Jennifer Hallman, RN, BSN 717-531-0003 ext 287412  
[jhallman@pennstatehealth.psu.edu](mailto:jhallman@pennstatehealth.psu.edu)  
Principal Investigator: Rogerio Neves, MD

**United States, Texas**

M.D. Anderson Cancer Center **Recruiting**  
Houston, Texas, United States, 77030  
Contact: Donna Branham 713-563-3527 [dbranham@mdanderson.org](mailto:dbranham@mdanderson.org)  
Principal Investigator: Merrick Ross, M.D.

**United States, Utah**



Huntsman Cancer Institute **Recruiting**  
Salt Lake City, Utah, United States, 84112  
Contact: Tamara Willis 801-587-4767 [Tamara.Willis@hci.utah.edu](mailto:Tamara.Willis@hci.utah.edu)  
Principal Investigator: Robert Andtbacka, M.D.

#### Australia, Queensland

Princess Alexandra Hospital **Recruiting**  
Brisbane, Queensland, Australia, 4102  
Contact: Janine Thomas +61 (07) 3844-8500 [Janine.thomas@mater.uq.edu.au](mailto:Janine.thomas@mater.uq.edu.au)  
Principal Investigator: Mark Smithers, M.D.

#### Germany

Department of Dermatology, University Hospital Schleswig-Holstein **Not yet recruiting**  
Kiel, Germany

#### Italy

IRCCS Istituto Nazionale Tumori "Fondazione Giovanni Pascale" **Recruiting**  
Napoli, Italy

Istituto Dermopatico dell'Immacolata (IDI IRCCS) **Recruiting**  
Rome, Italy

Azienda Sanitaria Azienda Ospedaliera Universitaria Senese **Recruiting**  
Siena, Italy

#### Sponsors and Collaborators

Provectus Biopharmaceuticals, Inc.

#### Investigators

Study Director: Eric Wachter, Ph.D. Provectus Biopharmaceuticals, Inc.

Principal Investigator: Sanjiv Agarwala, M.D. St Luke's University Hospital and Health Network



#### More Information

Responsible Party: Provectus Biopharmaceuticals, Inc.  
ClinicalTrials.gov Identifier: [NCT02288897](#) [History of Changes](#)  
Other Study ID Numbers: **PV-10-MM-31**  
First Submitted: November 4, 2014  
First Posted: November 11, 2014  
Last Update Posted: September 26, 2017  
Last Verified: September 2017

Keywords provided by Provectus Pharmaceuticals ( Provectus Biopharmaceuticals, Inc. ):

Stage III	IV(M1a)
Stage IIIB	IV-M1a
Stage IIIC	in-transit
Stage IV (M1a)	in transit
Stage 3	intransit
Stage 4	satellite
IVM1a	recurrent

Additional relevant MeSH terms:

Melanoma	Nevi and Melanomas
Neuroendocrine Tumors	Temozolomide
Neuroectodermal Tumors	Antineoplastic Agents, Alkylating
Neoplasms, Germ Cell and Embryonal	Alkylating Agents
Neoplasms by Histologic Type	Molecular Mechanisms of Pharmacological
Neoplasms	Action
Neoplasms, Nerve Tissue	Antineoplastic Agents